Bendamustine effective for some B-cell patients



Results from a study published in the journal Cancer suggest that patients with indolent B-cell non-Hodgkin’s lymphoma (iNHL) are responding well to Bendamustine, a chemo drug generally used to treat chronic lymphocytocic leukemia and some NHLs.


Professor Brad S. Kahl of the University of Wisconsin School of Medicine and Public Health, Maddison, USA


100 patients aged 31-84 years with indolent NHL who had undergone an average of two chemotherapies prior to enrolment and all were rituximab-refractory.


Drug: Bendamustine, a nitrogen mustard anticancer alkylating agent.
Regimen: The patients received intravenous infusions over 60-120 minutes, of bendamustine 120mg/m2 on days one and two every 21 days, for six to eight cycles.


Overall response rate (ORR): 75%
Complete response: 14%
Unconfirmed complete response: 3%
Partial response: 58%


Grade III or IV reversible haematological toxicities included:
-- Neutropenia (61%)
-- Thrombocytopenia (25%)
-- Anaemia (10%).

The most frequent non-haematological adverse events (any grade) included:
-- Nausea (77%)
-- Infection (69%)
-- Fatigue (64%)
-- Diarrhoea (42%)
-- Vomiting (40%)
-- Pyrexia (36%)
-- Constipation (31%)
-- Anorexia (24%).


Two of every three patients who had become rituximab-refractory responded well to the Bendamustine, and that's a good sign since rituximab immunotherapy is cutting edge stuff.

In one sense it's good to see there's another treatment option for B-cell patients whose lymphomas have become daity-refractory, but by and large this looks like little more than the pharmaceutical company's efforts to get their drugs approved for as many maladies as possible, since this iinevitably means more profits.

by Ross Bonander

More Articles

More Articles is pleased to have the Lymphoma Information Network in the family of associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics


At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...